{"id":"W4223516367","doi":"10.1186/s13063-022-06198-9","title":"Safety, tolerability, and efficacy of monoclonal CD38 antibody felzartamab in late antibody-mediated renal allograft rejection: study protocol for a phase 2 trial","year":2022,"lang":"en","type":"article","venue":"Trials","topic":"Renal Transplantation Outcomes and Treatments","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"The Metabolomics Innovation Centre; University of Alberta","funders":"MorphoSys","keywords":"Medicine; Tolerability; Monoclonal antibody; Antibody; CD38; Clinical trial; Protocol (science); Immunology; Pharmacology; Internal medicine; Pathology; Adverse effect; Alternative medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01040705,0.005010919,0.006165406,0.0009318978,0.001792774,0.002242884,0.002932723,0.005358419,0.02555443],"category_scores_gemma":[0.006879017,0.001855701,0.002408293,0.001050538,0.00211576,0.002427028,0.001069884,0.0053899,0.006009258],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002270695,"about_ca_system_score_gemma":0.008236866,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009370284,"about_ca_topic_score_gemma":0.002461366,"domain_scores_codex":[0.9950877,0.002778364,0.0003296809,0.0005482758,0.0004768059,0.0007792552],"domain_scores_gemma":[0.9959044,0.0006229877,0.000932764,0.0005482943,0.0006290959,0.00136249],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.9514871,0.02152745,0.0005719381,0.001479063,0.0003907042,0.0001226086,0.0001049658,0.0007868658,0.006024058,0.0004884408,0.004085558,0.01293122],"study_design_scores_gemma":[0.9197791,0.07019709,0.001162344,0.0001369102,0.0002009468,0.00005237689,0.0000247936,0.0005012559,0.0007248229,0.000431652,0.006754451,0.00003420942],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"protocol","genre_gemma":"protocol","genre_scores_codex":[0.1014435,0.002068453,0.004418159,0.001169641,0.0007860633,0.8786367,0.005005241,0.0004148736,0.006057353],"genre_scores_gemma":[0.08565346,0.001463459,0.006819252,0.001918139,0.0004862731,0.8954153,0.002231966,0.00005566364,0.005956559],"genre_candidate":"protocol","genre_consensus":"protocol","teacher_disagreement_score":0.02555443,"threshold_uncertainty_score":0.08548802,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1237729237190012,"score_gpt":0.4877437489362226,"score_spread":0.3639708252172213,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}